Zai Lab (ZLAB) stock has drawn fresh attention after recent trading swings, with the share price at $19.22 and performance over the past year showing sizable declines alongside mixed shorter term returns.

The recent pullback, including a 1-day share price return that fell 2.34% and a 7-day share price return down 4.85%, sits against a 1-year total shareholder return decline of 48.29%. This signals that long term momentum has been weak despite pockets of short term strength.

If you are weighing Zai Lab against other opportunities in the sector, this is a useful moment to size it up alongside 40 healthcare AI stocks.

That recent swing in Zai Lab, set against years of weak shareholder returns but growing reported revenue and collaborations, raises a simple tension: is a business with these fundamentals actually being offered at a reasonable price today?

Most Popular Narrative: 42.3% Undervalued

The most followed narrative for Zai Lab compares a fair value of about $33.30 to the current $19.22 share price, highlighting a wide gap that rests on ambitious growth and margin assumptions.

Multiple high-potential product launches and label expansions over the next 12-18 months (including VYVGART, bemarituzumab, KarXT, TIVDAK, Tumor Treating Fields), combined with a deep pipeline in oncology and immunology, are expected to significantly increase Zai Lab's addressable market and diversify revenue streams, supporting both top-line growth and future earnings.

What factors does this narrative suggest could support a much higher valuation for that product lineup? It focuses on rapidly rising revenue, a substantial margin change, and a premium future earnings multiple.

Result: Fair Value of $33.30 (UNDERVALUED)

However, this Zai Lab narrative could be knocked off course if competition in China erodes drug revenues or if high R&D and SG&A spending keeps profitability distant.

Next Steps

If the mixed sentiment on Zai Lab so far leaves you on the fence, consider taking a moment to weigh both sides and form your own stance with the 3 key rewards and 1 important warning sign

Looking for more investment ideas beyond Zai Lab?

If Zai Lab has you rethinking your portfolio mix, use this moment to line up a few fresh stock ideas so you are not relying on a single story.

• Target reliable income by reviewing companies in the 9 dividend fortresses that may help support a steadier return profile.
• Spot potential mispricings early by scanning the screener containing 19 high quality undiscovered gems and see which under-the-radar stocks match your criteria.
• Reduce portfolio stress by focusing on resilience with the 79 resilient stocks with low risk scores, highlighting companies that may better withstand shocks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.